A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome

Phase 1 Completed 39 enrolled Janssen Pharmaceutical K.K.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to to determine the recommended dose level of JNJ-30979754 (decitabine) as well as to assess the safety and effectiveness in patients with Myelodysplastic Syndrome (MDS).

Timeline

Start: 2008-07
Primary completion: 2010-10
Completion: 2010-10

Publications

Oki Y, Kondo Y, Yamamoto K, Ogura M, Kasai M, Kobayashi Y, Watanabe T, Uike N, Ohyashiki K, Okamoto S, Ohnishi K, Tomita A, Miyazaki Y, Tohyama K, Mukai HY, Hotta T, Tomonaga M. Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan. Cancer Sci. 2012 Oct;103(10):1839-47. doi: 10.1111/j.1349-7006.2012.02386.x. Epub 2012 Sep 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JNJ-30979754	Unknown	15 mg/m2	Intravenous
Subject	JNJ-30979754	Unknown	20 mg/m2	Intravenous

A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome

Summary

Timeline

Publications

Drugs

Indications